(Press-News.org) Tirzepatide is a recently approved treatment for type-2 diabetes. Treatment with tirzepatide decreases body weight while improving glucose metabolism in patients with obesity and type-2 diabetes. Although the drug is designed to activate receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), the contribution of activating the GIP receptor in the overall efficacy of tirzepatide is not fully understood. A team of researchers demonstrated for the first time that tirzepatide stimulates insulin secretion in the human pancreas via the GIP receptor. These results contrast with findings in mice, where Tirzepatide primarily stimulated insulin secretion via the GLP-1 receptor. This study is now published in Nature Metabolism.
Globally, type-2 diabetes and obesity are on the rise, with prevalence rates having tripled since the 1980’s, according to the WHO. Both diseases are associated with an impaired insulin action and treatment options are explored extensively, including those that target relevant hormone receptors. Two clinically validated targets are the receptors for glucagon-like peptide-1 (GLP-1) and for glucose-dependent insulinotropic polypeptide (GIP). Both receptors increase insulin secretion upon activation. Tirzepatide is a once-weekly GIP receptor and GLP-1 receptor agonist. It is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide has been shown to decrease food intake and modulate fat utilization. It is in phase 3 development for adults with obesity, or overweight with weight-related comorbidity. It is also being studied as a potential treatment for people with obesity and/or overweight with heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea (OSA), and non-alcoholic steatohepatitis (NASH). Studies of tirzepatide in chronic kidney disease (CKD) and in morbidity/mortality in obesity (MMO) are also ongoing.
Activation of The Human GIP Receptor Tirzepatide Enhances Insulin Secretion
While the co-agonist tirzepatide improves glucose control in patients with type-2 diabetes with superior efficacy compared with selective GLP-1 receptor agonists, the role of the GIP receptor in mediating these effects was unknown until now. Scientists from Helmholtz Munich, the German Center for Diabetes Research, Eli Lilly and Company, Novo Nordisk and the Duke University discovered that signaling via the GIP receptor in human pancreatic islets is crucial to stimulate insulin secretion. They were able to show that pharmacologically blocking the GIP receptor reduces the effectiveness of tirzepatide to stimulate insulin secretion from human islets. At the same time, blockade of the GLP-1 receptor had relatively marginally effects. These findings affirm the importance of GIP receptor signaling in the mechanism of action of tirzepatide. “These data are very interesting and demonstrate the importance of the GIP receptor in the metabolic action of tirzepatide”, summarizes Dr Jon Campbell, group leader at Duke University and senior author of the study.
Furthermore, the scientists evaluated the pharmacology of tirzepatide at the human and mouse receptors and compared its mode of action in isolated pancreatic islets from mice and human donors. “Similar to human GIP, tirzepatide shows weaker potency on the mouse GIP receptor, indicating that tirzepatide seems to work differently in mice and man”, notes Dr Timo Müller, Director of the Institute for Diabetes and Obesity at Helmholtz Munich and one of the corresponding authors. “While tirzepatide favors in the mouse the GLP-1 receptor to stimulate islet insulin secretion, it primarily acts via the GIP receptor in humans to boost insulin secretion”, adds Müller. “In subsequent studies, we will now assess how important the GIP receptor is for the body weight lowering effect of the drug”, says Kyle Sloop, a scientist at Eli Lilly and Company and corresponding author of the study.
Original publication
El and Douros et al. (2023): The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature Metabolism. DOI: 10.1038/s42255-023-00811-0.
END
Unraveling the mode of action of tirzepatide
2023-06-05
ELSE PRESS RELEASES FROM THIS DATE:
Study shows promising treatment for tinnitus
2023-06-05
Tinnitus, the ringing, buzzing or hissing sound of silence, varies from slightly annoying in some to utterly debilitating in others. Up to 15% of adults in the United States have tinnitus, where nearly 40% of sufferers have the condition chronically and actively seek relief.
A recent study from researchers at the University of Michigan’s Kresge Hearing Research Institute suggests relief may be possible.
Susan Shore, Ph.D., Professor Emerita in Michigan Medicine’s Department of Otolaryngology and U-M’s Departments of Physiology and Biomedical Engineering, led research on how the brain processes bi-sensory ...
BORIS gene mutation and expression: Link to breast cancer progression
2023-06-05
“The current study analyzed the correlation between BORIS mutations and the expression of the protein in breast cancer cases.”
BUFFALO, NY- June 5, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.”
The brother of the regulator of imprinted sites (BORIS), 11 zinc-finger transcription factors, ...
Healthy vascular fat during menopause may stave off dementia later in life
2023-06-05
The research, published in the journal Alzheimer’s & Dementia, is further evidence that the menopause transition is a particularly important time for women and their doctors to pay attention to heart health, in turn protecting their brain health.
“It is shocking to know that two-thirds of Americans with Alzheimer’s disease are women,” said Meiyuzhen (Chimey) Qi, first author and Ph.D. candidate in epidemiology at Pitt Public Health. “The most common modifiable risk factor for dementia is cardiovascular disease, and, interestingly, a woman’s ...
Germline genetic testing after cancer diagnosis – this study is being released to coincide with presentation at the 2023 ASCO Annual Meeting
2023-06-05
About The Study: Among patients diagnosed with cancer in California and Georgia between 2013 and 2019, only 6.8% underwent germline genetic testing. Compared with non-Hispanic white patients, rates of testing were lower among Asian, Black, and Hispanic patients.
Authors: Allison W. Kurian, M.D., M.Sc., of Stanford University in Stanford, California, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.9526)
Editor’s Note: Please see the article for additional information, ...
A simple blood test can now diagnose De Vivo disease
2023-06-05
Glut1 deficiency syndrome is a rare and disabling neurological disease still relatively unknown to the medical community. A mutation in the SLC2A1 gene in affected patients causes the glucose transporter GLUT1 to malfunction. Since this transporter is responsible for the glucose entering glial cells, the brain is deprived of some of the sugar it needs to function correctly, leading to seizures, bouts of abnormal movement, and developmental delays.
These symptoms can be improved by managing the metabolic disorder that causes the disease via a high-fat ...
Amid volumes of mobile location data, new framework reduces consumers’ privacy risk, preserves advertisers’ utility
2023-06-05
The use of mobile technologies to collect and analyze individuals’ location information has produced massive amounts of consumer location data, giving rise to an elaborate multi-billion-dollar system in which consumers can share personal data in exchange for economic benefits. But privacy risks prevail.
In a new study, researchers used machine learning to create and test a framework that quantifies personalized privacy risks; performs personalized data obfuscation; and accommodates a variety of risks, utilities, and acceptable levels of risk-utility tradeoff. The framework ...
Early universe crackled with bursts of star formation, Webb shows
2023-06-05
Among the most fundamental questions in astronomy is: How did the first stars and galaxies form? NASA’s James Webb Space Telescope is already providing new insights into this question. One of the largest programs in Webb’s first year of science is the JWST Advanced Deep Extragalactic Survey, or JADES, which will devote about 32 days of telescope time to uncover and characterize faint, distant galaxies. While the data is still coming in, JADES already has discovered hundreds of galaxies that existed when the universe was less than 600 million years old. The team also has identified galaxies sparkling with a multitude of young, hot ...
NASA’s Webb Space Telescope peers behind bars
2023-06-05
A delicate tracery of dust and bright star clusters threads across this image from the James Webb Space Telescope. The bright tendrils of gas and stars belong to the barred spiral galaxy NGC 5068, whose bright central bar is visible in the upper left of this image – a composite from two of Webb’s instruments. NASA Administrator Bill Nelson revealed the image Friday during an event with students at the Copernicus Science Centre in Warsaw, Poland.
NGC 5068 lies around 20 million light-years from Earth in the constellation Virgo. This image of the central, bright star-forming regions ...
New digital tool enables farmer’s decisions for sustainable agriculture
2023-06-05
A new ‘digital decision support tool’ enabling the transition towards more diversified and sustainable agricultural systems has been developed by an international team of researchers from Germany, France, and Czech Republic.
The research led by Dr Ioanna Mouratiadou from the Leibniz Centre for Agricultural Landscape Research, and published in Environmental Science and Ecotechnology, presents the ‘Digital Agricultural Knowledge and Information System (DAKIS)’ as a data integration ...
CRISPR/Cas9 reveals a key gene involved in the evolution of coral skeleton formation
2023-06-05
Baltimore, MD—New work led by Carnegie’s Phillip Cleves uses cutting-edge CRISPR/Cas9 genome editing tools to reveal a gene that’s critical to stony corals’ ability to build their reef architectures. It is published in Proceedings of the National Academy of Sciences.
Stony corals are marine invertebrates that build large skeletons, which form the basis of reef ecosystems. These biodiversity hotspots are home to about a quarter of known marine species.
“Coral reefs have ...